What is a stock summary page? Click here for an overview.
Business Description
Akebia Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US00972D1054
Compare
Compare
Traded in other countries / regions
AKBA.USAAX9.Germany Index Membership
Russell 2000Russell 3000Russell 2000 IPO Date
2014-03-20Description
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.09 | |||||
| Equity-to-Asset | -0.22 | |||||
| Debt-to-Equity | -0.97 | |||||
| Debt-to-EBITDA | -3.47 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -9.13 | |||||
| Beneish M-Score | -3.25 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -15.9 | |||||
| 3-Year EBITDA Growth Rate | 63.8 | |||||
| 3-Year EPS without NRI Growth Rate | 42.3 | |||||
| 3-Year FCF Growth Rate | 49.8 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 32.66 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 91.43 | |||||
| 9-Day RSI | 76.95 | |||||
| 14-Day RSI | 67.23 | |||||
| 3-1 Month Momentum % | -18.07 | |||||
| 6-1 Month Momentum % | 22.64 | |||||
| 12-1 Month Momentum % | 46.62 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.41 | |||||
| Quick Ratio | 1.21 | |||||
| Cash Ratio | 0.64 | |||||
| Days Inventory | 117.66 | |||||
| Days Sales Outstanding | 73.93 | |||||
| Days Payable | 75.45 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.3 | |||||
| Shareholder Yield % | -4.3 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 60.56 | |||||
| Operating Margin % | -31.47 | |||||
| Net Margin % | -43.33 | |||||
| FCF Margin % | -25.38 | |||||
| ROA % | -31.12 | |||||
| ROIC % | -30.92 | |||||
| 3-Year ROIIC % | -81.07 | |||||
| ROC (Joel Greenblatt) % | -314.41 | |||||
| ROCE % | -36.86 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3.15 | |||||
| EV-to-EBIT | -11.54 | |||||
| EV-to-EBITDA | -43.1 | |||||
| EV-to-Revenue | 3.69 | |||||
| EV-to-Forward-Revenue | 3.43 | |||||
| EV-to-FCF | -14.54 | |||||
| Price-to-GF-Value | 3.13 | |||||
| Earnings Yield (Greenblatt) % | -8.67 | |||||
| FCF Yield % | -6.54 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AKBA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Akebia Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 160.18 | ||
| EPS (TTM) ($) | -0.33 | ||
| Beta | 0.67 | ||
| 3-Year Sharpe Ratio | 0.7 | ||
| 3-Year Sortino Ratio | 1.61 | ||
| Volatility % | 71.36 | ||
| 14-Day RSI | 67.23 | ||
| 14-Day ATR ($) | 0.153585 | ||
| 20-Day SMA ($) | 1.919 | ||
| 12-1 Month Momentum % | 46.62 | ||
| 52-Week Range ($) | 0.8 - 2.89 | ||
| Shares Outstanding (Mil) | 261.23 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Akebia Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Akebia Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Akebia Therapeutics Inc Frequently Asked Questions
What is Akebia Therapeutics Inc(AKBA)'s stock price today?
The current price of AKBA is $2.38. The 52 week high of AKBA is $2.89 and 52 week low is $0.80.
When is next earnings date of Akebia Therapeutics Inc(AKBA)?
The next earnings date of Akebia Therapeutics Inc(AKBA) is 2025-05-09 Est..
Does Akebia Therapeutics Inc(AKBA) pay dividends? If so, how much?
Akebia Therapeutics Inc(AKBA) does not pay dividend.
Guru Commentaries on NAS:AKBA
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers